Computational approaches for drug repurposing in oncology: untapped opportunity for high value innovation.
| Autor: | Dalwadi SM; Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States., Hunt A; Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States., Bonnen MD; Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States., Ghebre YT; Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in oncology [Front Oncol] 2023 May 18; Vol. 13, pp. 1198284. Date of Electronic Publication: 2023 May 18 (Print Publication: 2023). |
| DOI: | 10.3389/fonc.2023.1198284 |
| Abstrakt: | Historically, the effort by academia and industry to develop new chemical entities into lifesaving drugs has limited success in meeting the demands of today's healthcare. Repurposing drugs that are originally approved by the United States Food and Drug Administration or by regulatory authorities around the globe is an attractive strategy to rapidly develop much-needed therapeutics for oncologic indications that extend from treating cancer to managing treatment-related complications. This review discusses computational approaches to harness existing drugs for new therapeutic use in oncology. Competing Interests: YG is an inventor on patents, owned by Stanford University and Baylor College of Medicine, that protect the development of proton pump inhibitors PPIs for therapeutic use of new indications including radiation dermatitis. YG and MB are inventors on the patent owned by Baylor College of Medicine. SD is involved in clinical trials that aim to repurpose the PPIs for new indications. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Dalwadi, Hunt, Bonnen and Ghebre.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|